Haiwang Changjian, a subsidiary of Neptune Interlon (08329), and Huikang Biotech signed a “Joint Venture Agreement” to establish a joint venture

According to Zhitong Finance App, Haiwang Interlon (08329) announced that on September 14, 2026 (after the trading period), Haiwang Changjian, a wholly-owned subsidiary of the Company, and Huikang Biotech (a non-wholly-owned subsidiary of Jin Baihui) signed a “Joint Venture Operation Agreement” to establish a joint venture. According to the joint venture agreement, the proposed registered capital of the joint venture is RMB 5 million, of which Haiwang Changjian has pledged an investment of RMB 3.5 million (accounting for 70% of the joint venture company's shares) and Huikang Biotech has pledged an investment of RMB 1.5 million (accounting for 30% of the joint venture company's shares). All parties shall pay the agreed capital within 1 year from the date the joint venture company completes its commercial registration.

The contracting parties agreed to jointly fund the establishment of a joint venture to position itself as a company focusing on the field of early tumor screening and in vitro diagnosis (IVD) to provide products, sales and overall solutions. The organizational form of a joint venture company is a limited liability company. Shareholders are liable to the company up to the amount of capital pledged by each. The joint venture company is responsible for its debts with all assets. The operating period is tentatively set for 10 years, starting from the date the business license is issued. The business scope of the joint venture is tentatively defined as: technical services, technology development, technical consultation, technical exchange, technology transfer, technology promotion; health consulting services (excluding diagnosis and treatment services); data processing services; sales of Class I and Class II medical devices; sales of medical consumables; import and export of goods and technology, etc., subject to approval and registration by the industry and commerce department.

The Group continues to advance its strategic layout in fields related to healthcare and in vitro diagnosis. Through the establishment of a joint venture with Huikang Biotech, all parties will integrate resources in R&D, products, channels and markets to achieve technology transformation and commercialization on early tumor screening and IVD tracks, optimize product structure, improve operational efficiency and market coverage, and help the Group enrich its product line, expand market share, strengthen core competitiveness and enhance shareholder returns. The board of directors believes that the joint venture agreement is based on normal commercial terms. The terms are fair and reasonable, and conform to the overall interests of the Company and shareholders.